Chronic inflammatory diseases like psoriasis, Crohn’s disease (CD), multiple sclerosis (MS), rheumatoid arthritis (RA), and others are increasingly recognized as disease entities, where dysregulated cytokines contribute substantially to tissue-specific inflammation. A dysregulation in the IL-23/IL-17 axis can lead to inflammation of barrier tissues, whereas its role in internal organ inflammation remains less clear. Here we discuss the most recent developments in targeting IL-17 for the treatment of chronic inflammation in preclinical models and in patients afflicted with chronic inflammatory diseases.
Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
P. Zwicky and S. Unger contributed equally to this paper.
- Views Icon Views
- Share Icon Share
- Tools Icon Tools
- Search Site
Pascale Zwicky, Susanne Unger, Burkhard Becher; Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective. J Exp Med 6 January 2020; 217 (1): e20191123. doi: https://doi.org/10.1084/jem.20191123
Download citation file: